Abstract
Background: Serum hyaluronic acid and biochemical models which require hyaluronic acid analysis are commonly used as predictors of liver fibrosis in patients with chronic liver disease, however biological variation data for hyaluronic acid are deficient.
Methods: Four serial serum samples were obtained at weekly intervals from healthy volunteers and patients with chronic hepatitis B, chronic hepatitis C and non- alcoholic fatty liver disease (NAFLD; 20 in each group). The within-individual week-to-week variation (CVI) and reference change values for hyaluronic acid, α2-macroglobulin and Hepascore were obtained. Hepascore is calculated from hyaluronic acid, α2-macroglobulin, bilirubin and γ-glutamyltransferase activity.
Results: Hyaluronic acid displayed large within-individual variation, the CVI values were 62% in healthy subjects, 38% in hepatitis C, 37% in hepatitis B and 36% in NAFLD patients. Hepascore CVIs were 43% in healthy subjects, 24% in hepatitis C, 28% in hepatitis B and 39% in NAFLD patients. α2-Macroglobulin was much less variable with CVIs ranging from 4.4% to 7.6%. Bland-Altman plots of week-to-week variations showed rates of significant disagreement for samples collected in any 2 successive weeks varied from 5% in NAFLD patients to 8.3% in healthy subjects.
Conclusions: When using non-fasting serum samples, hyaluronic acid and to a lesser extent, the Hepascore model display large within-individual variations in both health and chronic liver disease. This information is critical for interpreting the significance of both single measurements and changes in serial measurements.
We gratefully acknowledge the efforts of PathWest QE II medical scientists in the Special Chemistry section who performed the required laboratory tests.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
References
1. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437–41.10.1136/gut.36.3.437Search in Google Scholar PubMed PubMed Central
2. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898–906.10.1053/j.gastro.2005.03.084Search in Google Scholar PubMed
3. Adams LA. Biomarkers of liver fibrosis. Gastroenterol Hepatol 2011;26:802–9.10.1111/j.1440-1746.2010.06612.xSearch in Google Scholar PubMed
4. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatology 2011;53:2107–10.10.1002/hep.24401Search in Google Scholar PubMed
5. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867–73.10.1373/clinchem.2005.048389Search in Google Scholar PubMed
6. Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, et al. Comparison of non-invasive models of fibrosis in chronic hepatitis B. Hepatol Int 2012;6:457–.10.1007/s12072-011-9296-5Search in Google Scholar PubMed
7. Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011;26:1536–43.10.1111/j.1440-1746.2011.06774.xSearch in Google Scholar PubMed
8. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004;127:1704–13.10.1053/j.gastro.2004.08.052Search in Google Scholar PubMed
9. Vrochides D, Papanikolaou V, Pertoft H, Antoniades AA, Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration. Hepatology 1996;23:1650–5.10.1002/hep.510230648Search in Google Scholar PubMed
10. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003;18:253–7.10.1046/j.1440-1746.2003.02930.xSearch in Google Scholar PubMed
11. Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005;4:6.10.1186/1476-5926-4-6Search in Google Scholar
12. Tran A, Hastier P, Barjoan EM, Demuth N, Pradier C, Saint-Paul MC, et al. Non invasive prediction of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol 2000;24:626–30.Search in Google Scholar
13. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779–86.10.1111/j.1478-3231.2005.01064.xSearch in Google Scholar
14. Crawford DH, Murphy TL, Ramm LE, Fletcher LM, Clouston AD, Anderson GJ, et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009;49:418–25.10.1002/hep.22650Search in Google Scholar
15. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373–81.10.1002/hep.20935Search in Google Scholar
16. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935–42.10.1016/j.jhep.2004.08.008Search in Google Scholar
17. Guéchot J, Lasnier E, Sturm N, Paris A, Zarski JP; ANRS HC EP 23 Fibrostar study group. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta 2010;411:86–91.10.1016/j.cca.2009.10.011Search in Google Scholar
18. Fraser CG. Biological variation: from principles to practice. Washington: AACC Press, 2001:73–5.Search in Google Scholar
19. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Lond) 1998;95:179–86.10.1042/CS19980020Search in Google Scholar
20. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001;357:1069–75.10.1016/S0140-6736(00)04258-6Search in Google Scholar
21. http://www.westgard.com/biodatabase1.htm#top. Accessed September, 2011.Search in Google Scholar
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307–10.Search in Google Scholar
23. Bruins S, Fokkema MR, Römer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052–8.10.1373/clinchem.2004.038752Search in Google Scholar PubMed
24. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:1086–90.10.1373/clinchem.2009.140616Search in Google Scholar PubMed
25. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–93.10.1002/hep.510240201Search in Google Scholar PubMed
26. Lindqvist U, Engström-Laurent A, Laurent U, Nyberg A, Björklund U, Eriksson H, et al. The diurnal variation of serum hyaluronan in health and disease. Scand J Clin Lab Invest 1988;48:765–70.10.3109/00365518809088758Search in Google Scholar PubMed
27. Rössler A, László Z, Kvas E, Hinghofer-Szalkay HG. Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans. Eur J Appl Physiol Occup Physiol 1998;78:573–7.10.1007/s004210050463Search in Google Scholar PubMed
28. Hinghofer-Szalkay HG, Mekonen W, Rössler A, Schwaberger G, Lamprecht M, Hofmann P. Post-exercise decrease of plasma hyaluronan: increased clearance or diminished production? Physiol Res 2002;51:139–44.Search in Google Scholar
29. Fraser JR, Laurent TC, Engström-Laurent A, Laurent UG. Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 1984;11:17–25.10.1111/j.1440-1681.1984.tb00235.xSearch in Google Scholar PubMed
30. Idobe Y, Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Post-prandial serum hyaluronan concentration in patients with chronic liver disease. Intern Med 1998;37:568–75.10.2169/internalmedicine.37.568Search in Google Scholar PubMed
31. Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Intern Med 2005;258:460–6.10.1111/j.1365-2796.2005.01564.xSearch in Google Scholar PubMed
32. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012;56:55–62.10.1016/j.jhep.2011.05.024Search in Google Scholar PubMed
33. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010;10:103.10.1186/1471-230X-10-103Search in Google Scholar PubMed PubMed Central
34. Frébourg T, Delpech B, Bercoff E, Senant J, Bertrand P, Deugnier Y, et al. Serum hyaluronate in liver diseases: study by enzymoimmunological assay. Hepatology 1986;6:392–5.10.1002/hep.1840060310Search in Google Scholar PubMed
35. http://www.corgenixonline.com. Accessed September, 2011.Search in Google Scholar
36. Wong CS, Gibson PR. Effects of eating on plasma hyaluronan in patients with cirrhosis: its mechanism and influence on clinical interpretation. J Gastroenterol Hepatol 1998;13: 1218–24.10.1111/j.1440-1746.1998.tb00608.xSearch in Google Scholar
37. Majeed M, McQueen F, Yeoman S, McLean L. Relationship between serum hyaluronic acid level and disease activity in early rheumatoid arthritis. Ann Rheum Dis 2004;63:1166–8.10.1136/ard.2003.010942Search in Google Scholar PubMed PubMed Central
©2013 by Walter de Gruyter Berlin Boston
